There is a cure for autoimmune diabetes
What We Do
We develop therapies using our in-licensed substances GAD and GABA for the prevention or treatment of diabetes and other serious inflammatory diseases
Diamyd Medical is a Swedish clinical-stage diabetes company active in the field of pharmaceutical development.
Two disease-modifying therapies are being developed, the antigen-specific immunotherapy Diamyd® and the oral regenerative and immunomodulatory therapy Remygen®.
Diamyd® and Remygen® target the underlying causes of diabetes, the dysfunction and loss of the pancreatic beta cells. Diamyd® and Remygen® are currently being evaluated in clinical trials.
Diamyd Medical’s shares are traded on Nasdaq First North, ticker DMYD B.